Navigation Links
Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
Date:8/29/2010

.

About Teriflunomide

Teriflunomide is a new oral disease modifier for RMS that blocks de novo pyrimidine synthesis thus reducing T- and B-cells proliferation with no cytotoxicity. A comprehensive clinical development program for teriflunomide has been launched in monotherapy. First Phase II study results of the safety and efficacy of teriflunomide monotherapy in MS were published in Neurology in 2006. In addition to the TEMSO trial, two other Phase III trials, TOWER and TENERE, are ongoing in RMS. A Phase III study, TOPIC, is also underway in early MS or Clinically Isolated Syndrome (CIS). Teriflunomide has also been evaluated as an adjunct therapy to either interferon 1-beta or glatiramer acetate in two Phase II studies. Results of these studies were presented earlier this year during the American Committee for Treatment and Research in Multiple Sclerosis meeting (ACTRIMS) congress, and the American Academy of Neurology (AAN) meeting respectively. Phase II studies with teriflunomide (7mg and 14mg) in adjunct with interferon 1-beta demonstrated an improvement in outcomes, with a consistent safety profile in patients treated with the adjunct treatment compared with patients treated with IFN-beta and receiving placebo. In the other Phase II study, teriflunomide in adjunct to glatiramer acetate (GA) was well-tolerated compared to patients receiving GA and placebo. Although there was a numerical trend for the reduction in number and volume of gadolinium enhancing T-1 brain MRI lesions in the adjunct arm compared to placebo with GA, the relative effect was not as robust as that observed for teriflunomide with IFN-beta.

About TEMSO Study

TEMSO is a 2-year randomized, double-blind, placebo controlled study including 1088 RMS patients worldwide, aged 18-55 years, with an Expanded Disability Status Scale (EDSS) <= 5.5 and at least one relapse over the previous year or at least 2 relapses over the preceding 2 years. Patients were randomized
'/>"/>

SOURCE Sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
2. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
3. Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
4. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
5. Study Shows Machine Perfusion Significantly Improves Transplant Results
6. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
7. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
8. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
9. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
10. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
11. Buehler Motor, Inc., Significantly Expands Customer and Partner Support in North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... TORONTO , July 28, 2014 /PRNewswire/ -   ... latest group of companies to join its growing portfolio ... hallmarks of Toronto,s JOLT accelerator, ... startups on the roster. Since its ... that have successfully raised  $7.5M of financing. Now at ...
(Date:7/28/2014)... July 28, 2014 Appistry, Inc. ... that bring the power of genomics to next-generation medicine, ... Appistry Pipeline Challenge . , Two Appistry staff ... the National Center for Genome Resources, and Mr. Neil ... Clinics of Kansas City. Rounding out the panel are ...
(Date:7/28/2014)... , July 28, 2014 Research and Markets ... Size Analysis Market 2014-2018" report to their offering. ... size analysis is a technique used to determine the size ... liquid. It is crucial to analyze the size of particles ... particle size analysis is performed to determine the behavior and ...
(Date:7/25/2014)... in each person,s digestive tract. Scientists believe that some ... harmful infections, but their role in human health is ... the role of these bacteria, a team of researchers ... fluctuations in the bacterial populations of two research subjects ... July 25 issue of the journal Genome Biology ...
Breaking Biology Technology:JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2Global Particle Size Analysis Market 2014-2018 2Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3
... as an early warning system for potential ecological ... at Stockholm University and the University of East ... and food production are of fundamental importance for ... sudden changes in ecosystems caused by various pressures ...
... Receives Positive Committee Recommendation in European UnionSAN MATEO, Calif., ... ), a biopharmaceutical company focused on developing and commercializing ... a conference call on Friday, March 20, 2009 at ... quarter and year-end 2008 results and the European Medicines ...
... Indicated for Peripheral Neuropathic Pain in Non-Diabetic AdultsConference ... SAN MATEO, Calif., March 19 NeurogesX, ... company focused on developing and commercializing novel pain ... Agency,s (EMEA) Committee for Medicinal Products for Human ...
Cached Biology Technology:Internet can warn of ecological changes 2Internet can warn of ecological changes 3NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update 2NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update 3NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update 4NeurogesX' Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union 2NeurogesX' Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union 3NeurogesX' Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union 4NeurogesX' Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union 5NeurogesX' Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union 6
(Date:7/25/2014)... this false-color image from the Terra satellite show the different ... wildfires in Eastern Russia. The burn scars show up ... The wildfires have broken across the remote parts of Eastern ... image from the MODIS instrument, it is still possible ... Two recent image features noted below show the devastating number ...
(Date:7/25/2014)... and disrupted brain development is an essential part ... largely unknown. However, thanks to funding from the ... University (GW) researcher Anthony-Samuel LaMantia, Ph.D. may be ... to these key questions in the field of ... and physiology at the GW School of Medicine ...
(Date:7/25/2014)... 25 countries and 35 states will attend the ... Society of America (GSA) next week at the ... feature close to 500 presentations (including 70 talks) ... expression and regulation, functional genomics, chemical biology and ... variety of diseases. , Of special note ...
Breaking Biology News(10 mins):GW researcher receives grant to answer the how and why of autism during development 2Yeast meeting to showcase latest breakthroughs in genetics and molecular biology 2
... State Universitys computational mathematical sciences program in ... will power a new set of undergraduate ... $1 million grant from the National Science ... in computational mathematical sciences, will initially offer ...
... the Neural Basis of Cognition (CNBC), a joint project ... have for the first time described a mechanism called ... the fly allowing stimuli to be more keenly sensed. ... the January 2008 issue of Nature Neuroscience, and available ...
... simulations provide the first concrete molecular explanation of how ... into two daughter cells at the end of each ... Cell biologists at Yale and physicists at Columbia ... a cell assembles the contractile ring, the short-lived force-producing ...
Cached Biology News:Computational mathematical sciences receives NSF grant for undergraduate research 2Computational mathematical sciences receives NSF grant for undergraduate research 3Neuronal circuits able to rewire on the fly to sharpen senses 2How molecular muscles help cells divide 2
... HRP Conjugation Kits are based on ... that are consistent and reproducible. This ... conjugate your protein or antibody, including ... buffer. Activated HRP is supplied ...
... Acridinium NHS ester can be ... nucleic acids. The covalently bound ... chemiluminescence in the presence of ... proteins can be used as ...
... designed to hold up to 6 strain chambers ... easy to use design ensures that cells grow ... stretching or compression. This unit allows you to ... to produce 64 unique strain settings. The instrument ...
... a novel procedure for the uniform amplification ... genome DNA from small samples. This method ... and highly reproducible amplification and labeling procedure ... REPLI-g Mini Kit module (QIAGEN) and a ...
Biology Products: